Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Insmed Incorporated - Common Stock (NQ:INSM)

164.91 +3.91 (+2.43%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insmed Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Insmed (INSM) Q4 2025 Earnings Call Transcript ↗
Insmed (INSM) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗
Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗
Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗
This clinical-stage biotech develops therapies for NASH and obesity, advancing a diverse pipeline of small-molecule drug candidates. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress ↗
Praxis Precision Medicines develops therapies for central nervous system disorders, with candidates targeting depression and epilepsy. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million ↗
This clinical-stage biotech develops monoclonal antibody therapies targeting chronic inflammatory and immunological diseases. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
From Pomerantz LLP
Via GlobeNewswire
News headline image
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib ↗
Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh capital. 
Via The Motley Fool
Topics Stocks
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
From Pomerantz LLP
Via GlobeNewswire
News headline image
INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line ↗
Selling shares usually signals doubt, but in this case the math points to something very different happening beneath the surface. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Insmed Stock Plunges Nearly 20% After Hours As Sinus Drug Fails Mid-Stage Trial And Shows No Benefit ↗
While the drug was well tolerated with no new safety concerns, the drug yielded no positive treatment benefits in a study even at its highest dose of 40 mg. 
Via Stocktwits
News headline image
Wondering what's happening in today's after-hours session? ↗
As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗
One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗
PTC’s turnaround quarter is raising eyebrows—here’s why one major investor just doubled down. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an... 
Via MarketMinute
News headline image
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
From BioMedWire
Via GlobeNewswire
News headline image
30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks ↗
Stanley Druckenmiller is considered one of the greatest investors of all time. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Billionaire Stanley Druckenmiller Just Bet Big on This Hot IPO Stock. Is It a Buy? ↗
This online ticket marketplace debuted in September, but has struggled thus far. 
Via The Motley Fool
Topics ETFs Initial Public Offering Regulatory Compliance
News headline image
Peering Into Insmed Inc's Recent Short Interest ↗
 
Via Benzinga
News headline image
Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves ↗
Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven asset allocation. 
Via Benzinga
News headline image
If You Invested $1000 In Insmed Stock 10 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
This Investor Sold $1.9 Million in AMSC Stock Ahead of 35% Post-Earnings Crash ↗
This Investor Sold $1.9 Million in AMSC Stock Ahead of 35% Post-Earnings Crash 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Essex Investment Buys $7.1 Million Globalstar Stake as Revenue Hits Record High ↗
Essex Investment Buys $7.1 Million Globalstar Stake as Revenue Hits Record High 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Here's How Much $1000 Invested In Insmed 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday? ↗
Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome... 
Via Benzinga
Topics Economy
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.